Serum S100B protein as a marker of severity in Covid-19 patients

Abstract SARS-CoV-2 infection shows a wide-ranging clinical severity, requiring prognostic markers. We focused on S100B, a calcium-binding protein present in biological fluids, being a reliable biomarker in disorders having inflammatory processes as common basis and RAGE as main receptor. Since Covi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Aceti, Lory Marika Margarucci, Elena Scaramucci, Massimiliano Orsini, Gerardo Salerno, Gabriele Di Sante, Gianluca Gianfranceschi, Rosa Di Liddo, Federica Valeriani, Francesco Ria, Maurizio Simmaco, Pier Paolo Parnigotto, Matteo Vitali, Vincenzo Romano Spica, Fabrizio Michetti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5409d3c41f13418f86eca67929c851f6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5409d3c41f13418f86eca67929c851f6
record_format	dspace
spelling	oai:doaj.org-article:5409d3c41f13418f86eca67929c851f62021-12-02T15:10:10ZSerum S100B protein as a marker of severity in Covid-19 patients10.1038/s41598-020-75618-02045-2322https://doaj.org/article/5409d3c41f13418f86eca67929c851f62020-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-75618-0https://doaj.org/toc/2045-2322Abstract SARS-CoV-2 infection shows a wide-ranging clinical severity, requiring prognostic markers. We focused on S100B, a calcium-binding protein present in biological fluids, being a reliable biomarker in disorders having inflammatory processes as common basis and RAGE as main receptor. Since Covid-19 is characterized by a potent inflammatory response also involving RAGE, we tested if S100B serum levels were related to disease severity. Serum samples (n = 74) were collected from hospitalized SARS-CoV-2 positive patients admitted to Covid center. Illness severity was established by admission clinical criteria and Covid risk score. Treatment protocols followed WHO guidelines available at the time. Circulating S100B was determined by ELISA assay. Statistical analysis used Pearson’s χ2 test, t-Test, and ANOVA, ANCOVA, Linear Regression. S100B was detected in serum from Covid-19 patients, significantly correlating with disease severity as shown both by the level of intensity of care (p < 0.006) as well by the value of Covid score (Multiple R-squared: 0.3751); the correlation between Covid-Score and S100B was 0.61 (p < 0.01). S100B concentration was associated with inflammation markers (Ferritin, C-Reactive Protein, Procalcitonin), and organ damage markers (Alanine Aminotransferase, Creatinine). Serum S100B plays a role in Covid-19 and can represent a marker of clinical severity in Sars-CoV-2 infected patients.Antonio AcetiLory Marika MargarucciElena ScaramucciMassimiliano OrsiniGerardo SalernoGabriele Di SanteGianluca GianfranceschiRosa Di LiddoFederica ValerianiFrancesco RiaMaurizio SimmacoPier Paolo ParnigottoMatteo VitaliVincenzo Romano SpicaFabrizio MichettiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Antonio Aceti Lory Marika Margarucci Elena Scaramucci Massimiliano Orsini Gerardo Salerno Gabriele Di Sante Gianluca Gianfranceschi Rosa Di Liddo Federica Valeriani Francesco Ria Maurizio Simmaco Pier Paolo Parnigotto Matteo Vitali Vincenzo Romano Spica Fabrizio Michetti Serum S100B protein as a marker of severity in Covid-19 patients
description	Abstract SARS-CoV-2 infection shows a wide-ranging clinical severity, requiring prognostic markers. We focused on S100B, a calcium-binding protein present in biological fluids, being a reliable biomarker in disorders having inflammatory processes as common basis and RAGE as main receptor. Since Covid-19 is characterized by a potent inflammatory response also involving RAGE, we tested if S100B serum levels were related to disease severity. Serum samples (n = 74) were collected from hospitalized SARS-CoV-2 positive patients admitted to Covid center. Illness severity was established by admission clinical criteria and Covid risk score. Treatment protocols followed WHO guidelines available at the time. Circulating S100B was determined by ELISA assay. Statistical analysis used Pearson’s χ2 test, t-Test, and ANOVA, ANCOVA, Linear Regression. S100B was detected in serum from Covid-19 patients, significantly correlating with disease severity as shown both by the level of intensity of care (p < 0.006) as well by the value of Covid score (Multiple R-squared: 0.3751); the correlation between Covid-Score and S100B was 0.61 (p < 0.01). S100B concentration was associated with inflammation markers (Ferritin, C-Reactive Protein, Procalcitonin), and organ damage markers (Alanine Aminotransferase, Creatinine). Serum S100B plays a role in Covid-19 and can represent a marker of clinical severity in Sars-CoV-2 infected patients.
format	article
author	Antonio Aceti Lory Marika Margarucci Elena Scaramucci Massimiliano Orsini Gerardo Salerno Gabriele Di Sante Gianluca Gianfranceschi Rosa Di Liddo Federica Valeriani Francesco Ria Maurizio Simmaco Pier Paolo Parnigotto Matteo Vitali Vincenzo Romano Spica Fabrizio Michetti
author_facet	Antonio Aceti Lory Marika Margarucci Elena Scaramucci Massimiliano Orsini Gerardo Salerno Gabriele Di Sante Gianluca Gianfranceschi Rosa Di Liddo Federica Valeriani Francesco Ria Maurizio Simmaco Pier Paolo Parnigotto Matteo Vitali Vincenzo Romano Spica Fabrizio Michetti
author_sort	Antonio Aceti
title	Serum S100B protein as a marker of severity in Covid-19 patients
title_short	Serum S100B protein as a marker of severity in Covid-19 patients
title_full	Serum S100B protein as a marker of severity in Covid-19 patients
title_fullStr	Serum S100B protein as a marker of severity in Covid-19 patients
title_full_unstemmed	Serum S100B protein as a marker of severity in Covid-19 patients
title_sort	serum s100b protein as a marker of severity in covid-19 patients
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/5409d3c41f13418f86eca67929c851f6
work_keys_str_mv	AT antonioaceti serums100bproteinasamarkerofseverityincovid19patients AT lorymarikamargarucci serums100bproteinasamarkerofseverityincovid19patients AT elenascaramucci serums100bproteinasamarkerofseverityincovid19patients AT massimilianoorsini serums100bproteinasamarkerofseverityincovid19patients AT gerardosalerno serums100bproteinasamarkerofseverityincovid19patients AT gabrieledisante serums100bproteinasamarkerofseverityincovid19patients AT gianlucagianfranceschi serums100bproteinasamarkerofseverityincovid19patients AT rosadiliddo serums100bproteinasamarkerofseverityincovid19patients AT federicavaleriani serums100bproteinasamarkerofseverityincovid19patients AT francescoria serums100bproteinasamarkerofseverityincovid19patients AT mauriziosimmaco serums100bproteinasamarkerofseverityincovid19patients AT pierpaoloparnigotto serums100bproteinasamarkerofseverityincovid19patients AT matteovitali serums100bproteinasamarkerofseverityincovid19patients AT vincenzoromanospica serums100bproteinasamarkerofseverityincovid19patients AT fabriziomichetti serums100bproteinasamarkerofseverityincovid19patients
_version_	1718387752431517696

Serum S100B protein as a marker of severity in Covid-19 patients

Ejemplares similares